Embecta stock may seem undervalued at first glance, but heavy debt, declining pen needle revenues, and competition signal ...

competitive factors that could adversely affect embecta’s operations; (ii) any inability to replace the services provided by Becton, Dickinson and Company (“BD”) under the transaction ...

competitive factors that could adversely affect embecta’s operations; (ii) any inability to replace the services provided by Becton, Dickinson and Company (“BD”) under the transaction ...

diabetes management company Embecta Corp. (EMBC), which was spun-off from medical technology company Becton, Dickinson and Co. (BDX), maintained its adjusted earnings guidance for the full-year ...

PARSIPPANY, N.J., May 09, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta” or ... related to sales of non-diabetes products to Becton, Dickinson and Company ("BD"). 2 Other includes product ...

Becton Dickinson & Co., an American medical equipment company ... the spin-off of the diabetes care unit into a public company under the brand name of Embecta Corp. and she sold the surgical ...

PARSIPPANY, N.J., May 22, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta"; "The Company") (Nasdaq: EMBC), a global diabetes care company with a 100-year legacy in insulin delivery, will host its ...

(MENAFN- GlobeNewsWire - Nasdaq) PARSIPPANY, N.J., May 09, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta” or the "Company") (Nasdaq: EMBC), a global diabetes ...